Hearken to this text
A New Orleans-based biotech firm has developed a breakthrough non-opioid ache medicine, which is backed by funding from Ochsner Ventures, the funding arm of Ochsner Well being, and from Gulf South Angels (GSA), the area’s main angel investor community. 
South Rampart Pharma, Inc. publicizes that it has secured funding to advance Section 2 medical trials of its lead novel non-opioid, SRP-001, a first-of-its-kind non-opioid ache medicine.
Backed by Gulf South Angels and Ochsner Ventures, this financing represents the preliminary closing and launches the corporate’s ongoing Collection A spherical ($8 million). To get to this stage, the corporate utilized $9 million between non-dilutive and dilutive funding, in comparison with trade requirements, that are usually round $50 million.
“We imagine SRP-001 has the potential to ship immense social profit by providing a non-addictive ache administration choice at a time when our nation desperately wants it,” stated Mike Eckert, GSA Board Chairman. “This class is overdue for innovation, and South Rampart Pharma is main the best way.”
The financing represents one of many largest investments made by GSA to this point. GSA is a community of greater than 140 accredited buyers with sturdy roots in southeast Louisiana and members throughout the U.S. GSA can also be actively syndicating the chance to angel investor teams nationwide, bringing new capital and a focus into the New Orleans’ rising biotech sector.
Ochsner Well being, the main nonprofit healthcare supplier within the Gulf South with 46 hospitals and greater than 370 well being and pressing care facilities, continues to take a position strategically in improvements that align with the well being system’s objectives of delivering safer, simpler healthcare and increasing entry to cutting-edge therapies and options.
Based in 2016 by physician-scientists Dr. Hernan Bazan and Dr. Nicolas Bazan, South Rampart Pharma has developed SRP-001 – a first-in-class analgesic that targets the midbrain’s PAG (periaqueductal gray) area with out opioid abuse potential or acetaminophen’s liver toxicity. Constructive Section 1 trial information confirmed SRP-001’s security and strong pharmacokinetics, with Section 2 information anticipated in This autumn 2025. The remedy earned FDA’s Quick Monitor designation for acute ache, highlighting the pressing want and vital potential for accelerated growth.
“GSA’s sturdy participation in our ongoing Collection A financing is a crucial milestone, and helps place us to advance SRP-001 as a differentiated therapeutic resolution in ache,” stated Dr. Hernan Bazan, CEO of South Rampart Pharma. “We imagine SRP-001 has the potential to handle a big hole within the ache market, providing a safer therapeutic method designed to keep away from the dependancy dangers of opioids and the toxicity considerations of current analgesics.”
